Biomarker ID | 63 |
PMID | 15655565 |
Year | 2005 |
Biomarker | COX-2 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Patients with relapse |
Odds Ratio/Hazard Ratio/Relative Risk | RH: 4.68 (95% CI: 0.6-37.1) |
Effect on Pathways | Pathways Include:-Selenium pathway,C-Myb transcription factor network, VEGF signaling pathway, Leishmaniasis,Prostaglandin biosynthesis and regulation |
Experiment | PCa Relapse Vs No Relapse |
Type of Biomarker | Prognostic |
Cohort | 126 patients were chosen for the study and divided into 2 groups- Early Stage (clinically localized disease) (n=72) and Late Stage Metastatic AI disease (n=54). 30 patients experienced relapse |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.01 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | COX-2, bcl-2 and MVD (Microvessel Density) for neoangiogenesis were chosen for biomarker evaluation |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | PTGS2 |